{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T21:07:14Z","timestamp":1696367234733},"reference-count":140,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.gtc.2006.05.001","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:09:23Z","timestamp":1168441763000},"page":"487-505","source":"Crossref","is-referenced-by-count":3,"title":["HIV-Related Liver Disease: Infections Versus Drugs"],"prefix":"10.1016","volume":"35","author":[{"given":"Homayon","family":"Sidiq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Ankoma-Sey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2006.05.001_bib1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.285.10.1308","article-title":"Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States 1984\u20131997","volume":"285","author":"Lee","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gtc.2006.05.001_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/s-2005-864780","article-title":"Treatment of chronic hepatitis C in human immunodeficiency virus\/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavarin","volume":"25","author":"Br\u00e4u","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib3","unstructured":"Klein MB, Lalonde RG, Suissa S. Hepatitis C (HCV) coinfection is associated with increased morbidity and mortality among HIV-infected patients. Presented at The 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 4\u20138, 2001."},{"issue":"16","key":"10.1016\/j.gtc.2006.05.001_bib4","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1097\/00002030-200311070-00002","article-title":"Update on chronic hepatitis C in HIV\/HCV-coinfected patients: viral interactions and therapy","volume":"17","author":"Br\u00e4u","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1086\/319747","article-title":"Mortality among human deficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine\/Infectious Diseases, in 1995 and 1997","volume":"32","author":"Cacoub","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib6","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1086\/368186","article-title":"Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999\u20132000","volume":"36","author":"Jain","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-138-3-200302040-00012","article-title":"Hepatitis C in the HIV-infected person","volume":"138","author":"Sulkowski","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002030-200401020-00001","article-title":"Care of patients with hepatitis C and HIV co-infection Updated recommendations from the HIV-HCV International Panel","volume":"18","author":"Soriano","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2006.05.001_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1473-3099(04)01059-X","article-title":"HIV\/HCV coinfection","volume":"4","author":"Rockstroh","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2105\/AJPH.91.1.42","article-title":"Sharing of drug preparation equipment as a risk factor for hepatitis C","volume":"91","author":"Hagan","year":"2001","journal-title":"Am J Public Health"},{"key":"10.1016\/j.gtc.2006.05.001_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0163-4453(03)00067-7","article-title":"Hepatitis C virus and human immunodeficiency virus coinfection in Spain","volume":"47","author":"Roca","year":"2003","journal-title":"J Infect"},{"key":"10.1016\/j.gtc.2006.05.001_bib14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ije\/dyg107","article-title":"Influence of maternal human immunodeficiency (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis","volume":"32","author":"Pappalardo","year":"2003","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.gtc.2006.05.001_bib16","first-page":"2071","article-title":"Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area","volume":"97","author":"Br\u00e4u","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.gtc.2006.05.001_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.qco.0000191509.56104.ec","article-title":"New paradigms in the management of HIV and hepatitis C virus coinfection","volume":"18","author":"Soriano","year":"2005","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/00002030-199510000-00003","article-title":"High hepatitis C viremia and impaired antibody response in patients coinfected with HIV","volume":"9","author":"Cribier","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib19","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V94.4.1183","article-title":"Low levels of HCV RNA in serum, plasma, and PBMCs of IDUs during long antibody-undetectable periods before seroconversion","volume":"94","author":"Beld","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.gtc.2006.05.001_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00126334-200210010-00005","article-title":"Hepatitis C viremia in HIV-infected individuals with negative HCV antibody tests","volume":"31","author":"George","year":"2002","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1016\/j.gtc.2006.05.001_bib21","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1128\/JCM.31.10.2679-2682.1993","article-title":"Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections","volume":"31","author":"Sherman","year":"1993","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.gtc.2006.05.001_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2893.1999.00153.x","article-title":"Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA","volume":"6","author":"Bonacini","year":"1999","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gtc.2006.05.001_bib23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivaric Group","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2006.05.001_bib24","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.52.7.1035","article-title":"Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients","volume":"52","author":"Mohsen","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.05.001_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/367643","article-title":"Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus","volume":"36","author":"Martinez-Sierra","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0168-8278(02)00413-0","article-title":"A comparison of fibrosis progression in chronic liver disease","volume":"38","author":"Poynard","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2006.05.001_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2006.05.001_bib28","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(97)05413-5","article-title":"Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organization","volume":"350","author":"Darby","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.05.001_bib29","unstructured":"Di Martino V, Ezenfis J, Tainturier MH, et al. Impact of HIV coinfection on the long-term outcome of HCV cirrhosis. Presented at The 9th Conference on Retroviruses and Opportunistic Infections. Chicago, February 4\u20138, 2001."},{"key":"10.1016\/j.gtc.2006.05.001_bib30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: host, viral, and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2006.05.001_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-132-2-200001180-00003","article-title":"45-year follow-up of hepatitis C virus infection in healthy young adults","volume":"132","author":"Seeff","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/jhep.2001.26517","article-title":"Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy","volume":"34","author":"Benhamou","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2006.05.001_bib33","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study","volume":"356","author":"Greub","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.05.001_bib34","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.162.18.2125","article-title":"Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously na\u00efve HIV-infected subjects","volume":"162","author":"De Luca","year":"2002","journal-title":"Arch Interm Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.288.2.199","article-title":"Hepatitis C and progression of HIV disease","volume":"288","author":"Sulkkowski","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2006.05.001_bib36","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/00002030-200207050-00007","article-title":"Is hepatitis C virus coinfection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?","volume":"16","author":"Rancinan","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib37","first-page":"244A","article-title":"Durability of sustained viral response in patients with chronic hepatitis C after treatment with interferon alfa02b alone or in combination with ribavarin","volume":"34","author":"McHutchison","year":"2001","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2006.05.001_bib38","first-page":"400A","article-title":"Durability of sustained virological response (SVR) after treatment with peg interferon alfa-2a (40KD) alone or in combination with ribavarin: result of an ongoing long-term follow-up study","volume":"40","author":"Swain","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2006.05.001_bib39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0168-8278(98)80274-2","article-title":"Long-term course of interferon-treated chronic hepatitis C","volume":"28","author":"Camma","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2006.05.001_bib40","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1943::AID-CNCR10>3.0.CO;2-F","article-title":"Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy","volume":"85","author":"Shindo","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.gtc.2006.05.001_bib41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510280430","article-title":"10-year follow-up after interferon-alpha therapy for chronic hepatitis C","volume":"28","author":"Lau","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2006.05.001_bib42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0168-8278(99)80129-9","article-title":"Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon","volume":"30","author":"Reichard","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2006.05.001_bib43","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peg interferon alfa-2b plus ribavarin compared with interferon alfa-2b plus ribavarin for initial treatment of chronic hepatitis C: a randomized trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.05.001_bib44","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peg interferon alfa-2a plus ribavarin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib45","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peg interferon\u2013alpha 2a and ribavarin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavarin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","article-title":"Histology improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy","volume":"132","author":"Shiratori","year":"2000","journal-title":"Ann Interm Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib47","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(95)91739-X","article-title":"Randomized trail of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis","volume":"346","author":"Nishiguchi","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.05.001_bib48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","article-title":"Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy","volume":"131","author":"Yoshida","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib49","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(00)03595-9","article-title":"Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis","volume":"357","author":"Nishiguchi","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.05.001_bib50","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/clinids\/23.3.585","article-title":"Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group","volume":"23","author":"Soriano","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib51","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peg interferon alfa-2a plus ribavarin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib52","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peg interferon alfa-2a plus ribavarin versus interferon alfa-2a plus ribavarin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib53","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2a vs. standard interferon afa-2b, plus ribavarin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2006.05.001_bib54","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peg interferon alfa-2b plus ribavarin compared with interferon alfa-2b plus ribavarin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib55","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199306243282501","article-title":"Risk factors for hepatocellular carcinoma among patients with chronic liver disease","volume":"328","author":"Tsukuma","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib56","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602333","article-title":"A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China","volume":"92","author":"Shi","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gtc.2006.05.001_bib57","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/169.5.990","article-title":"Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases","volume":"169","author":"Thomas","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib58","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/00002030-200405210-00010","article-title":"Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort","volume":"18","author":"Law","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","article-title":"Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort","volume":"19","author":"Konopnicki","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib60","first-page":"300","article-title":"Update on viral hepatitis in 2004","volume":"21","author":"Scott","year":"2005","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.gtc.2006.05.001_bib61","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.05.001_bib62","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1097\/00002030-200410210-00008","article-title":"Survival in patients with HIV infection and viral hepatitis B or C: a cohort study","volume":"18","author":"Bonacini","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib63","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/gut.32.3.294","article-title":"Natural history and prognostic factors for chronic hepatitis type B","volume":"32","author":"Fattovich","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.05.001_bib64","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/infdis\/163.5.1138","article-title":"The influence of human immunodeficiency virus type1 infection on the development of the hepatitis B virus carrier state","volume":"163","author":"Bodsworth","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib65","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/319368","article-title":"Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens","volume":"32","author":"Hoff","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib66","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.510300525","article-title":"Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2006.05.001_bib67","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/jinf.2000.0724","article-title":"Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus infected patient","volume":"41","author":"Neau","year":"2000","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.gtc.2006.05.001_bib68","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00126334-200004010-00013","article-title":"Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated","volume":"23","author":"Piroth","year":"2000","journal-title":"J Acquired Immune Defic Syndr"},{"key":"10.1016\/j.gtc.2006.05.001_bib69","first-page":"54","article-title":"Treating opportunistic infections among HIV-infected adults and adolescents","volume":"53","author":"Benson","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.gtc.2006.05.001_bib70","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/j.1572-0241.2000.01981.x","article-title":"Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection","volume":"95","author":"Rodriguez-Mendez","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.05.001_bib71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01584356","article-title":"Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only","volume":"17","author":"Hofer","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib72","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0016-5085(94)90735-8","article-title":"HIV infection and isolated detection of anti-HBc","volume":"106","author":"Vasquez-Vizoso","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.05.001_bib73","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0168-8278(05)80207-7","article-title":"Hepatitis B virus occult infection in subjects with persistent isolated antiHBc reactivity","volume":"17","author":"Sanchez-Quijano","year":"1993","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2006.05.001_bib74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0168-8278(95)80305-X","article-title":"Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus","volume":"23","author":"Jilg","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2006.05.001_bib75","first-page":"419","article-title":"The significance of the isolated anti-HBc carrier. A study of 1797 drug addicts","volume":"84","author":"Mezzalani","year":"1994","journal-title":"Recent Prog Med"},{"issue":"2","key":"10.1016\/j.gtc.2006.05.001_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/1096-9071(200010)62:2<151::AID-JMV5>3.0.CO;2-N","article-title":"Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53","volume":"62","author":"Shiota","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.gtc.2006.05.001_bib77","first-page":"51","article-title":"Hepatocellular carcinoma with occult chronic hepatitis-hepatitis B virus as a pathogenetic factor of hepatocellular carcinoma","volume":"34","author":"Koyama","year":"1988","journal-title":"Osaka City Med J"},{"key":"10.1016\/j.gtc.2006.05.001_bib78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1600-0676.1994.tb00084.x","article-title":"Pathology of livers infected with \u201csilent\u201d hepatitis B virus mutant","volume":"14","author":"Uchida","year":"1994","journal-title":"Liver"},{"key":"10.1016\/j.gtc.2006.05.001_bib79","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1023\/A:1018814700915","article-title":"Frequent detection of hepatitis B virus X-gene DNA in hepatocellular carcinoma and adjacent liver tissue in hepatitis B surface antigen-negative patients","volume":"42","author":"Takeuchi","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2006.05.001_bib80","first-page":"313","article-title":"Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma","volume":"21","author":"Paterlini","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2006.05.001_bib81","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(88)92891-7","article-title":"Transmission of hepatitis B from hepatitis\u2013B-seronegative subjects","volume":"2","author":"Thiers","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.05.001_bib82","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJM197806222982502","article-title":"Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen","volume":"298","author":"Hoofnagle","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib83","first-page":"27","article-title":"Hepatitis B virus co-infection in HIV-infected subjects","volume":"4","author":"Puoti","year":"2002","journal-title":"AIDS Rev"},{"key":"10.1016\/j.gtc.2006.05.001_bib84","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. A meta-analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib85","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/gast.2002.37061","article-title":"Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B","volume":"123","author":"Di Martino","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.05.001_bib86","first-page":"1030","article-title":"Serum alanine transaminase level is a good predictor of response to interferon therapy for chronic hepatitis B in HIV-infected patients","volume":"31","author":"Di Martino","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2006.05.001_bib87","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1473-3099(05)70141-9","article-title":"Management of patients co-infected with hepatitis B virus and HIV","volume":"5","author":"Nunez","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.gtc.2006.05.001_bib88","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2005-915646","article-title":"Management of HBV\/HIV-coinfected patients","volume":"25","author":"Shire","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib89","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/514750","article-title":"Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine","volume":"28","author":"Bessesen","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib90","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/gast.2002.30901","article-title":"Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV","volume":"122","author":"Bonacini","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.05.001_bib91","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","article-title":"Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study","volume":"358","author":"Benhamou","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.05.001_bib92","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/AAC.46.5.1586-1588.2002","article-title":"Human immunodeficiency (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine","volume":"45","author":"Delaugerre","year":"2002","journal-title":"Antimicro Agents Chemother"},{"key":"10.1016\/j.gtc.2006.05.001_bib93","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.20464","article-title":"Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection","volume":"40","author":"van Bommel","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2006.05.001_bib94","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/jhep.2001.26815","article-title":"Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection","volume":"34","author":"de Man","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2006.05.001_bib95","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/gast.2002.37058","article-title":"Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection","volume":"123","author":"Lai","year":"2002","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.gtc.2006.05.001_bib96","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/01.qai.0000179459.31562.16","article-title":"Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART eras","volume":"41","author":"Crum","year":"2006","journal-title":"J Acquir Defic Syndr"},{"key":"10.1016\/j.gtc.2006.05.001_bib97","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10096-002-0823-0","article-title":"Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy","volume":"21","author":"Macias","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib98","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/BF02390528","article-title":"Impact of HAART on causes of death of persons with late-stage AIDS","volume":"77","author":"Sansone","year":"2000","journal-title":"J Urban Health"},{"key":"10.1016\/j.gtc.2006.05.001_bib99","unstructured":"Wolfe MI, Hanson DL, Selik DL, et al. Deaths from non-AIDS-related diseases have increased as a proportion of deaths of HIV-infected persons since the advent of HAART. Presented at The Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February, 2002."},{"issue":"2","key":"10.1016\/j.gtc.2006.05.001_bib100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2003-39949","article-title":"Hepatotoxicity associated wit antiretroviral therapy containing HIV-1 protease inhibitors","volume":"23","author":"Sulkowski","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib101","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(01)00311-7","article-title":"Antiviral drug toxicity-a challenge for hepatologist?","volume":"36","author":"Splengler","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2006.05.001_bib102","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirpine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib103","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1086\/338638","article-title":"Abacavir expanded access program for adult patients infected with human immunodeficiency virus type1","volume":"34","author":"Kessler","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib104","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00002030-200101260-00027","article-title":"Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity","volume":"15","author":"Frissen","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib105","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00126334-200309011-00006","article-title":"Managing antiretroviral-associated liver disease","volume":"34","author":"Dieterich","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.gtc.2006.05.001_bib106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00042560-200201010-00005","article-title":"The LIVERHARRT Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection","volume":"29","author":"Aceti","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.gtc.2006.05.001_bib107","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/00002030-199810000-00025","article-title":"Hepatotoxicity after introduction of highly active antiretroviral therapy","volume":"12","author":"Rodriguez-Rosado","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib108","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/517808","article-title":"Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremic patients coinfected with HIV","volume":"177","author":"Rutschmann","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib109","first-page":"116","article-title":"Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy","volume":"12","author":"Vento","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib110","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/00002030-199817000-00010","article-title":"Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?","volume":"12","author":"John","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib111","unstructured":"Verdon R, Vabret A, Goubin P, et al. HIV-HCV coinfection: is HIV viral load decrease associated with HCV viral load variations. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 24\u201327, 1998."},{"key":"10.1016\/j.gtc.2006.05.001_bib112","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/520281","article-title":"Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects","volume":"26","author":"Zylberberg","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib113","series-title":"Schiff's diseases of the Liver","author":"Schiff","year":"2003"},{"key":"10.1016\/j.gtc.2006.05.001_bib114","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/00126334-200202011-00005","article-title":"Long-term exposure to lifelong therapies","volume":"29","author":"Powderly","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.gtc.2006.05.001_bib115","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1089\/apc.2005.19.356","article-title":"Hepatic steatosis and HIV infection","volume":"19","author":"Ristig","year":"2005","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib116","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00001432-200002000-00002","article-title":"Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?","volume":"13","author":"Brinkman","year":"2000","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib117","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/00002030-200211080-00009","article-title":"Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors","volume":"16","author":"Walker","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib118","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipoatrophy, lactic academia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome","volume":"14","author":"Carr","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib119","first-page":"47","article-title":"The fatty liver in AIDS","volume":"13","author":"Tien","year":"2002","journal-title":"Semin Gastrointest Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(03)00654-6","article-title":"Hyperlactatemia syndromes associated with HIV therapy","volume":"3","author":"Ogedegbe","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib121","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1097\/00002030-200006160-00033","article-title":"Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy","volume":"14","author":"Johri","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib122","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1086\/323783","article-title":"Symptomatic lactic acidosis in hospitalized antiretroviral treated patients with human immunodeficiency virus infection: a report of 12 cases","volume":"33","author":"Coghlan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.05.001_bib123","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/sti.77.3.158","article-title":"Mitochondrial toxicity and HIV therapy","volume":"77","author":"White","year":"2001","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.gtc.2006.05.001_bib124","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00002030-200104130-00007","article-title":"Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy","volume":"15","author":"John","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib125","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/00003246-199708000-00034","article-title":"Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature","volume":"8","author":"Sundar","year":"1997","journal-title":"Crit Care Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib126","unstructured":"US Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http:\/\/www.hivatis.org\/trtdlns.html. Accessed January 2005."},{"key":"10.1016\/j.gtc.2006.05.001_bib127","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib128","unstructured":"Crixivan\u00ae (indinavir sulfate) package insert. West Point (PA): Merck and Co., Inc; 1999."},{"key":"10.1016\/j.gtc.2006.05.001_bib129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1468-1293.2001.00063.x","article-title":"Principles and practice of HIV-protease inhibitor pharmacoenhancement","volume":"2","author":"Moyle","year":"2001","journal-title":"HIV Med"},{"issue":"8","key":"10.1016\/j.gtc.2006.05.001_bib130","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-129-8-199810150-00026","article-title":"Hepatotoxicity associated with Ritonavir","volume":"129","author":"Picard","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2006.05.001_bib131","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management","volume":"44","author":"Nunez","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2006.05.001_bib132","unstructured":"Viracept\u00ae (nelfinavir mesylate) package insert. La Jolla (CA): Agouron Pharmaceuticals, Inc.; 2001."},{"key":"10.1016\/j.gtc.2006.05.001_bib133","unstructured":"Agenerase\u00ae (amprenavir) package insert. Research Triangle Park (NC): GlaxoSmithKline, Inc.; 2002."},{"key":"10.1016\/j.gtc.2006.05.001_bib134","unstructured":"Norvir\u00ae (ritonavir capsules) package insert. North Chicago (IL): Abbott Laboratories; 2001."},{"key":"10.1016\/j.gtc.2006.05.001_bib135","unstructured":"Fortavase (saquinavir soft gelatin capsule) package insert. Nutley (NJ): Roche Laboratories, Inc; 2002."},{"key":"10.1016\/j.gtc.2006.05.001_bib136","unstructured":"Kaletra\u2122 (lopinavir\/ritonavir) package insert. North Chicago (IL): Abbott Laboratories; 2002."},{"key":"10.1016\/j.gtc.2006.05.001_bib137","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1073\/pnas.231140698","article-title":"Mechanism of indinavir-induced hyperbilirubinemia","volume":"98","author":"Zucker","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.gtc.2006.05.001_bib138","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy","volume":"15","author":"Martinez","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.gtc.2006.05.001_bib139","unstructured":"Boehringer-Ingelheim International Viramune product monograph, version 3.0. Ingelheim am Rhein, Germany: Boehringer-Ingelheim International GmbH."},{"key":"10.1016\/j.gtc.2006.05.001_bib140","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1086\/343046","article-title":"A cohort study of nevirapin tolerance in clinical practice: French Aquitaine cohort, 1997\u20131999","volume":"35","author":"Bonnet","year":"2002","journal-title":"Clin Infect Dis"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855306000306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855306000306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T17:46:46Z","timestamp":1587318406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855306000306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0889855306000306"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2006.05.001","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}